297 related articles for article (PubMed ID: 31007119)
41. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
Carver KH; Elikan J; Lietzan E
Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
[TBL] [Abstract][Full Text] [Related]
42. Biologic Drugs, Biosimilars, and Barriers to Entry.
Shepherd JM
Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
[TBL] [Abstract][Full Text] [Related]
43. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.
Mulcahy AW; Hlavka JP; Case SR
Rand Health Q; 2018 Mar; 7(4):3. PubMed ID: 30083415
[TBL] [Abstract][Full Text] [Related]
44. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
45. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
46. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
Shubow S; Sun Q; Nguyen Phan AL; Hammell DC; Kane M; Lyman GH; Gibofsky A; Lichtenstein GR; Bloomgarden Z; Cross RK; Yim S; Polli JE; Wang YM
Clin Pharmacol Ther; 2023 Jan; 113(1):37-49. PubMed ID: 36251545
[TBL] [Abstract][Full Text] [Related]
47. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
[TBL] [Abstract][Full Text] [Related]
48. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
Hernandez I; Gellad WF
J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
[TBL] [Abstract][Full Text] [Related]
49. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
50. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
51. Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement.
Ho RJ
J Pharm Sci; 2017 Feb; 106(2):471-476. PubMed ID: 27876365
[TBL] [Abstract][Full Text] [Related]
52. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
[TBL] [Abstract][Full Text] [Related]
53. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A
BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078
[TBL] [Abstract][Full Text] [Related]
54. FDA's Approach to Regulating Biosimilars.
Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
[TBL] [Abstract][Full Text] [Related]
55. Why Are Biosimilars Not Living up to Their Promise in the US?
Zhai MZ; Sarpatwari A; Kesselheim AS
AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
[TBL] [Abstract][Full Text] [Related]
56. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
57. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
[TBL] [Abstract][Full Text] [Related]
58. Top Evidentiary Gaps in Managed Care Pharmacy: A Research Agenda.
Gembarski J; Couto J; Wilson M;
J Manag Care Spec Pharm; 2020 Apr; 26(4):375-381. PubMed ID: 32130069
[TBL] [Abstract][Full Text] [Related]
59. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
60. Assessment of pharmacists' views on biosimilar naming conventions.
Fernandez-Lopez S; Kazzaz D; Bashir M; McLaughlin T
J Manag Care Spec Pharm; 2015 Mar; 21(3):188-95. PubMed ID: 25726028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
